Immunogenicity of Split Inactivated Quadrivalent Influenza Vaccine in Adults with Obesity in the 2017/2018 Season

Immunogenicity of Split Inactivated Quadrivalent Influenza Vaccine in Adults with Obesity in the 2017/2018 Season

BACKGROUND Obesity is associated with susceptibility to severe influenza infection and several disturbances of the immune response to the influenza vaccine. However, the effect of obesity on the immunogenicity of the influenza vaccine is not fully understood. Our objective here was to assess the imm...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Medical science monitor 2021-05, Vol.27, p.e929572-e929572
Hauptverfasser: Jagielska, Anna M, Brydak, Lidia B, Nitsch-Osuch, Aneta S
Format: Artikel
Sprache:eng
Schlagworte:
Clinical Research
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page e929572
container_issue
container_start_page e929572
container_title Medical science monitor
container_volume 27
creator Jagielska, Anna M
Brydak, Lidia B
Nitsch-Osuch, Aneta S
description BACKGROUND Obesity is associated with susceptibility to severe influenza infection and several disturbances of the immune response to the influenza vaccine. However, the effect of obesity on the immunogenicity of the influenza vaccine is not fully understood. Our objective here was to assess the immunogenicity of the split, inactivated quadrivalent influenza vaccine (QIV) in Polish adults with obesity. MATERIAL AND METHODS Fifty-three subjects with obesity aged 21-69 years were vaccinated with the QIV in 2017/2018 season. Antibody titers against the 4 vaccine strains were measured using the hemagglutination inhibition (HI) assay. The mean fold antibody increase (MFI), seroprotection rate (protection rate, PR), and seroconversion rate (response rate, RR) were calculated to assess vaccine immunogenicity. RESULTS The vaccine elicited a significant increase in the anti-HI titers against the QIV antigens. The MFI, PR, and RR for the QIV antigens also reached the required age-specific values, indicating the QIV meets current immunogenicity criteria. Individuals with class I and class II/III obesity had similar anti-HI titers, MFI, PR, and RR to each of the vaccine strains. Adults aged
doi_str_mv 10.12659/MSM.929572
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8139133</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2528435522</sourcerecordid><originalsourceid>FETCH-LOGICAL-c381t-ded64ed658e4988a6657d624fd7978046c9b0cffcb739ef976cc3f8804a24eee3</originalsourceid><addsrcrecordid>eNpVUU1LxDAQDaL4ffIuOQqymiZNmlwEWfxYUERWvYZsOnEjbbo2qaK_3uiq6GFmHvMebwYeQnsFOSqo4Or4enp9pKjiFV1Bm4Uo2YhVnKz-wRtoK8YnQqgUhK-jDcaUKjkTm-h50rZD6B4heOvTG-4cni4an_AkGJv8i0lQ49vB1H3GDYRPwjUDhHeDH4y1PgD2AZ_WQ5MifvVpjm9mED-t8jrNAVNSVMe5STwFE7uwg9acaSLsfs9tdH9-dje-HF3dXEzGp1cjy2SRRjXUoszFJZRKSiMEr2pBS1dXqpKkFFbNiHXOziqmwKlKWMuczIyhJQCwbXSy9F0MsxZqm3_vTaMXvW9N_6Y74_V_Jvi5fuxetCyYKhjLBgffBn33PEBMuvXRQtOYAN0QNeVUloxzSrP0cCm1fRdjD-73TEH0V0g6h6SXIWX1_t_PfrU_qbAP9vuOPA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2528435522</pqid></control><display><type>article</type><title>Immunogenicity of Split Inactivated Quadrivalent Influenza Vaccine in Adults with Obesity in the 2017/2018 Season</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central Open Access</source><source>PubMed Central</source><creator>Jagielska, Anna M ; Brydak, Lidia B ; Nitsch-Osuch, Aneta S</creator><creatorcontrib>Jagielska, Anna M ; Brydak, Lidia B ; Nitsch-Osuch, Aneta S</creatorcontrib><description>BACKGROUND Obesity is associated with susceptibility to severe influenza infection and several disturbances of the immune response to the influenza vaccine. However, the effect of obesity on the immunogenicity of the influenza vaccine is not fully understood. Our objective here was to assess the immunogenicity of the split, inactivated quadrivalent influenza vaccine (QIV) in Polish adults with obesity. MATERIAL AND METHODS Fifty-three subjects with obesity aged 21-69 years were vaccinated with the QIV in 2017/2018 season. Antibody titers against the 4 vaccine strains were measured using the hemagglutination inhibition (HI) assay. The mean fold antibody increase (MFI), seroprotection rate (protection rate, PR), and seroconversion rate (response rate, RR) were calculated to assess vaccine immunogenicity. RESULTS The vaccine elicited a significant increase in the anti-HI titers against the QIV antigens. The MFI, PR, and RR for the QIV antigens also reached the required age-specific values, indicating the QIV meets current immunogenicity criteria. Individuals with class I and class II/III obesity had similar anti-HI titers, MFI, PR, and RR to each of the vaccine strains. Adults aged &lt;60 years had similar anti-HI titers, MFI, PR, and RR to the QIV strains to those aged ≥60 years. CONCLUSIONS Our results indicate that the split virion, inactivated QIV is immunogenic in adults with obesity regardless of their degree of obesity and age (ie, &lt;60 and ≥60 years).</description><identifier>ISSN: 1643-3750</identifier><identifier>ISSN: 1234-1010</identifier><identifier>EISSN: 1643-3750</identifier><identifier>DOI: 10.12659/MSM.929572</identifier><identifier>PMID: 33994536</identifier><language>eng</language><publisher>United States: International Scientific Literature, Inc</publisher><subject>Clinical Research</subject><ispartof>Medical science monitor, 2021-05, Vol.27, p.e929572-e929572</ispartof><rights>Med Sci Monit, 2021 2021</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c381t-ded64ed658e4988a6657d624fd7978046c9b0cffcb739ef976cc3f8804a24eee3</citedby><orcidid>0000-0002-2622-7348 ; 0000-0003-0553-627X ; 0000-0003-0285-7385</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8139133/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8139133/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,53769,53771</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33994536$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jagielska, Anna M</creatorcontrib><creatorcontrib>Brydak, Lidia B</creatorcontrib><creatorcontrib>Nitsch-Osuch, Aneta S</creatorcontrib><title>Immunogenicity of Split Inactivated Quadrivalent Influenza Vaccine in Adults with Obesity in the 2017/2018 Season</title><title>Medical science monitor</title><addtitle>Med Sci Monit</addtitle><description>BACKGROUND Obesity is associated with susceptibility to severe influenza infection and several disturbances of the immune response to the influenza vaccine. However, the effect of obesity on the immunogenicity of the influenza vaccine is not fully understood. Our objective here was to assess the immunogenicity of the split, inactivated quadrivalent influenza vaccine (QIV) in Polish adults with obesity. MATERIAL AND METHODS Fifty-three subjects with obesity aged 21-69 years were vaccinated with the QIV in 2017/2018 season. Antibody titers against the 4 vaccine strains were measured using the hemagglutination inhibition (HI) assay. The mean fold antibody increase (MFI), seroprotection rate (protection rate, PR), and seroconversion rate (response rate, RR) were calculated to assess vaccine immunogenicity. RESULTS The vaccine elicited a significant increase in the anti-HI titers against the QIV antigens. The MFI, PR, and RR for the QIV antigens also reached the required age-specific values, indicating the QIV meets current immunogenicity criteria. Individuals with class I and class II/III obesity had similar anti-HI titers, MFI, PR, and RR to each of the vaccine strains. Adults aged &lt;60 years had similar anti-HI titers, MFI, PR, and RR to the QIV strains to those aged ≥60 years. CONCLUSIONS Our results indicate that the split virion, inactivated QIV is immunogenic in adults with obesity regardless of their degree of obesity and age (ie, &lt;60 and ≥60 years).</description><subject>Clinical Research</subject><issn>1643-3750</issn><issn>1234-1010</issn><issn>1643-3750</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNpVUU1LxDAQDaL4ffIuOQqymiZNmlwEWfxYUERWvYZsOnEjbbo2qaK_3uiq6GFmHvMebwYeQnsFOSqo4Or4enp9pKjiFV1Bm4Uo2YhVnKz-wRtoK8YnQqgUhK-jDcaUKjkTm-h50rZD6B4heOvTG-4cni4an_AkGJv8i0lQ49vB1H3GDYRPwjUDhHeDH4y1PgD2AZ_WQ5MifvVpjm9mED-t8jrNAVNSVMe5STwFE7uwg9acaSLsfs9tdH9-dje-HF3dXEzGp1cjy2SRRjXUoszFJZRKSiMEr2pBS1dXqpKkFFbNiHXOziqmwKlKWMuczIyhJQCwbXSy9F0MsxZqm3_vTaMXvW9N_6Y74_V_Jvi5fuxetCyYKhjLBgffBn33PEBMuvXRQtOYAN0QNeVUloxzSrP0cCm1fRdjD-73TEH0V0g6h6SXIWX1_t_PfrU_qbAP9vuOPA</recordid><startdate>20210517</startdate><enddate>20210517</enddate><creator>Jagielska, Anna M</creator><creator>Brydak, Lidia B</creator><creator>Nitsch-Osuch, Aneta S</creator><general>International Scientific Literature, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-2622-7348</orcidid><orcidid>https://orcid.org/0000-0003-0553-627X</orcidid><orcidid>https://orcid.org/0000-0003-0285-7385</orcidid></search><sort><creationdate>20210517</creationdate><title>Immunogenicity of Split Inactivated Quadrivalent Influenza Vaccine in Adults with Obesity in the 2017/2018 Season</title><author>Jagielska, Anna M ; Brydak, Lidia B ; Nitsch-Osuch, Aneta S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c381t-ded64ed658e4988a6657d624fd7978046c9b0cffcb739ef976cc3f8804a24eee3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Clinical Research</topic><toplevel>online_resources</toplevel><creatorcontrib>Jagielska, Anna M</creatorcontrib><creatorcontrib>Brydak, Lidia B</creatorcontrib><creatorcontrib>Nitsch-Osuch, Aneta S</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Medical science monitor</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jagielska, Anna M</au><au>Brydak, Lidia B</au><au>Nitsch-Osuch, Aneta S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immunogenicity of Split Inactivated Quadrivalent Influenza Vaccine in Adults with Obesity in the 2017/2018 Season</atitle><jtitle>Medical science monitor</jtitle><addtitle>Med Sci Monit</addtitle><date>2021-05-17</date><risdate>2021</risdate><volume>27</volume><spage>e929572</spage><epage>e929572</epage><pages>e929572-e929572</pages><issn>1643-3750</issn><issn>1234-1010</issn><eissn>1643-3750</eissn><abstract>BACKGROUND Obesity is associated with susceptibility to severe influenza infection and several disturbances of the immune response to the influenza vaccine. However, the effect of obesity on the immunogenicity of the influenza vaccine is not fully understood. Our objective here was to assess the immunogenicity of the split, inactivated quadrivalent influenza vaccine (QIV) in Polish adults with obesity. MATERIAL AND METHODS Fifty-three subjects with obesity aged 21-69 years were vaccinated with the QIV in 2017/2018 season. Antibody titers against the 4 vaccine strains were measured using the hemagglutination inhibition (HI) assay. The mean fold antibody increase (MFI), seroprotection rate (protection rate, PR), and seroconversion rate (response rate, RR) were calculated to assess vaccine immunogenicity. RESULTS The vaccine elicited a significant increase in the anti-HI titers against the QIV antigens. The MFI, PR, and RR for the QIV antigens also reached the required age-specific values, indicating the QIV meets current immunogenicity criteria. Individuals with class I and class II/III obesity had similar anti-HI titers, MFI, PR, and RR to each of the vaccine strains. Adults aged &lt;60 years had similar anti-HI titers, MFI, PR, and RR to the QIV strains to those aged ≥60 years. CONCLUSIONS Our results indicate that the split virion, inactivated QIV is immunogenic in adults with obesity regardless of their degree of obesity and age (ie, &lt;60 and ≥60 years).</abstract><cop>United States</cop><pub>International Scientific Literature, Inc</pub><pmid>33994536</pmid><doi>10.12659/MSM.929572</doi><orcidid>https://orcid.org/0000-0002-2622-7348</orcidid><orcidid>https://orcid.org/0000-0003-0553-627X</orcidid><orcidid>https://orcid.org/0000-0003-0285-7385</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1643-3750
ispartof Medical science monitor, 2021-05, Vol.27, p.e929572-e929572
issn 1643-3750
1234-1010
1643-3750
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8139133
source Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central Open Access; PubMed Central
subjects Clinical Research
title Immunogenicity of Split Inactivated Quadrivalent Influenza Vaccine in Adults with Obesity in the 2017/2018 Season
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T23%3A32%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immunogenicity%20of%20Split%20Inactivated%20Quadrivalent%20Influenza%20Vaccine%20in%20Adults%20with%20Obesity%20in%20the%202017/2018%20Season&rft.jtitle=Medical%20science%20monitor&rft.au=Jagielska,%20Anna%20M&rft.date=2021-05-17&rft.volume=27&rft.spage=e929572&rft.epage=e929572&rft.pages=e929572-e929572&rft.issn=1643-3750&rft.eissn=1643-3750&rft_id=info:doi/10.12659/MSM.929572&rft_dat=%3Cproquest_pubme%3E2528435522%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2528435522&rft_id=info:pmid/33994536&rfr_iscdi=true